ClinicalTrials.gg
CompletedNCT01280721Updated Jan 17, 2019Results posted

A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]

A Phase 3 interventional study of tolvaptan in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 7 sites in Japan. Open to participants aged 23 Years to 53 Years. Per ClinicalTrials.gov, last updated 2019-01-17.

Primary conditionPolycystic Kidney, Autosomal DominantRegistry: Polycystic Kidney DiseasesReclassifiedWhy we changed it
Registry
Polycystic Kidney Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Polycystic Kidney, Autosomal Dominant
Why
  1. The study's listed conditions name Polycystic Kidney, Autosomal Dominant, a narrower term within Polycystic Kidney Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Not applicable
Ages
23 Years to 53 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.

Enrollment
6th of 18
135 · median 91
Started
2010
with 3 others
Phase 3
8 of 18
none open now
Registered
7th of 18
by date
Lead sponsor
3 of 18
Otsuka Pharmaceutical Co., Ltd.

Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 6th largest by enrollment, is one of 4 that started in 2010, is one of 8 in phase 3, and was the 7th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 23 Years to 53 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant as a file.
02

Study summary

ADPKD patients who enrolled in Trial 156-04-251 will receive repeated oral administration of tolvaptan twice daily (morning and evening: 45mg/15mg, 60mg/30mg, or 90mg/30mg).

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Browse trials for

04

In context

Polycystic Kidney, Autosomal Dominant Reclassified

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

This study's enrollment of 135 is above the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.

Browse Polycystic Kidney, Autosomal Dominant studies →

Lead sponsor

Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.

Compared within Polycystic Kidney, Autosomal Dominant, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Polycystic Kidney Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
23 Years to 53 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who participated in Trial 156-04-251 in Japan and for whom CRF collection has been completed.
  • Patients who completed 3-year repeated administration and who completed the second follow-up visit or patients whose treatment with the trial drug was interupted due to pregnancy and who completed out the second follow-up visit in Trial 156-04-251.
  • Patients in whom any adverse events occurring in Trial 156-04-251 were resolved orstabilized and require no further follow-up.

Exclusion criteria

Exclusion Criteria:

  • Patients with of less than 15 mL/min/1.73 m2
  • Pregnant, breast-feeding, or possibly pregnant women or women who are planning to become pregnant
  • Patients who received any drug other than Tolvaptan within 30 days prior to commencement of administration of tolvaptan
  • Any patients who, in the opinion of the principle investigator or subinvestigators, should not participate in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    tolvaptan

    Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.

    Drug: tolvaptan

Interventions

  • Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.

07

What researchers measure

Primary outcomes

  1. Total Kidney Volume

    Measured values of total kidney volume (sum of the volume of the left and right kidneys) during trial period. Twice-daily repeated oral administration of tolvaptan at daily doses of 60 to 120 mg. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.

    Time frame: Baseline, Month12, Month24, and Month36

  2. Renal Function Test (eGFR)

    Estimated glomerular filtration rate calculated by Japanese equation for eGFR during trial period. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.

    Time frame: Baseline, Month12, Month24, and Month36

  3. Renal Function Test (Cys-C)

    Measured values of serum cystatin C concentration during trial period. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.

    Time frame: Baseline, Month 12, Month 24, and Month 36

08

Results

Posted Jan 17, 2019

Participant flow

Participant flow — Overall Study
MilestoneTolvaptan
Started135
Completed113
Not completed22
Withdrew: Adverse event4
Withdrew: Physician decision3
Withdrew: Withdrawal by subject6
Withdrew: Egfr under the withdrawal criteria7
Withdrew: No tolerability for the lowest dose2

Outcome measures

PrimaryTotal Kidney Volume

Measured values of total kidney volume (sum of the volume of the left and right kidneys) during trial period. Twice-daily repeated oral administration of tolvaptan at daily doses of 60 to 120 mg. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.

Time frame:
Baseline, Month12, Month24, and Month36
Reported as:
Mean · mL
Total Kidney Volume
mLBaselineMonth 12Month 24Month 36
Total Kidney Volume1812.38 ± 859.211878.82 ± 950.601934.14 ± 926.792214.28 ± 842.87
PrimaryRenal Function Test (eGFR)

Estimated glomerular filtration rate calculated by Japanese equation for eGFR during trial period. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.

Time frame:
Baseline, Month12, Month24, and Month36
Reported as:
Mean · mL/min/1.73 m2
Renal Function Test (eGFR)
mL/min/1.73 m2BaselineMonth 12Month 24Month 36
Renal Function Test (eGFR)61.2 ± 21.756.3 ± 21.751.8 ± 20.143.5 ± 20.3
PrimaryRenal Function Test (Cys-C)

Measured values of serum cystatin C concentration during trial period. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.

Time frame:
Baseline, Month 12, Month 24, and Month 36
Reported as:
Mean · mg/L
Renal Function Test (Cys-C)
mg/LBaselimeMonth 12Month 24Month 36
Renal Function Test (Cys-C)1.016 ± 0.4211.114 ± 0.4771.129 ± 0.4661.281 ± 0.461

Adverse events

Collected over Through study completion, 2 to 3 years for major patients. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tolvaptan0/135 (0%)20/135 (14.8%)134/135 (99.3%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventTolvaptan
Renal cyst infectionInfections and infestations4/135
Renal cyst haemorrhageRenal and urinary disorders2/135
Cardiac failure acuteCardiac disorders1/135
Angina pectorisCardiac disorders1/135
IleusGastrointestinal disorders1/135
Umbilical herniasGastrointestinal disorders1/135
AppendicitisInfections and infestations1/135
SepsisInfections and infestations1/135
Hepatic cyst infectionInfections and infestations1/135
Ligament ruptureInjury, poisoning and procedural complications1/135
Most frequent other events
Showing 10 of 93
Most frequent other events
EventTolvaptan
ThirstGeneral disorders104/135
NasopharyngitisInfections and infestations94/135
PollakiuriaRenal and urinary disorders77/135
PolyuriaRenal and urinary disorders52/135
Back painMusculoskeletal and connective tissue disorders30/135
HyperuricaemiaMetabolism and nutrition disorders29/135
HeadacheNervous system disorders26/135
DiarrhoeaGastrointestinal disorders21/135
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders21/135
InfluenzaInfections and infestations20/135

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Tolvaptan
<=18 years0
Between 18 and 65 years135
>=65 years0
Age, Continuous
Age, Continuous(years)Tolvaptan
Mean42.7 ± 5.9
Sex: Female, Male
Sex: Female, Male(Participants)Tolvaptan
Female77
Male58
Region of Enrollment
Region of Enrollment(participants)Tolvaptan
Japan135
09

Study locations

7 sites
  • Chubu Region, Japan
  • Chugoku Region, Japan
  • Hokkaido Region, Japan
  • Kanto Region, Japan
  • Kinki Region, Japan
  • Kyushu Region, Japan
  • Tohoku Region, Japan
10

References and documents

Publications

  • Muto S, Okada T, Yasuda M, Tsubouchi H, Nakajima K, Horie S. Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial. Drug Healthc Patient Saf. 2017 Oct 25;9:93-104. doi: 10.2147/DHPS.S142825. eCollection 2017. Erratum In: Drug Healthc Patient Saf. 2018 Jul 16;10:67-68. doi: 10.2147/DHPS.S175655. PubMed 29123425 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2019, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2010
First posted
Jan 21, 2011
Start
Nov 2010
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Jan 17, 2019
Last update
Jan 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01280721
Responsible party
Sponsor
First posted
Jan 21, 2011
Start date
Nov 2010
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Jan 17, 2019
Last update
Jan 17, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion